Covington & Burling advised Insmed Incorporated on the transaction. Insmed Incorporated (Nasdaq: INSM) (“Insmed”) announced its entrance into an agreement to amend its $350 million term...
Insmed’s $150 Million Credit Facility Upsize with Pharmakon
Bristol Myers Squibb’s $4.1 Billion Acquisition of RayzeBio
Covington advised Bristol Myers Squibb on the transaction, while Cooley and Wilson Sonsini Goodrich & Rosati advised RayzeBio Inc. Goodwin advised Centerview Partners in its role...
Alexion, AstraZeneca Rare Disease in Deal with Pfizer
Covington & Burling advised Alexion on the transaction while Arnold & Porter represented Pfizer. AstraZeneca Rare Disease announced its entry into a definitive purchase and license agreement...
AstraZeneca’s Acquisition of CinCor Pharma
Covington & Burling advised AstraZeneca. Skadden represented Centerview Partners LLC, the exclusive financial advisor to CinCor Pharma Inc. Cooley advised CinCor Pharma. CinCor Pharma Inc. (“CinCor”)...
Insmed Incorporated’s $775 Million Financing
Covington advised Insmed Incorporated on the deal while Fenwick represented Pharmakon. Walder Wyss advised the funds managed by Pharmakon Advisors, LP, BioPharma Credit and OrbiMed. Akin...